Vaccine May Benefit Certain Patients With Non-Small Cell Lung Cancer

Share this content:
Belagenpumatucel-L as maintenance therapy for non-small cell lung cancer may benefit patients.
Belagenpumatucel-L as maintenance therapy for non-small cell lung cancer may benefit patients.

Belagenpumatucel-L, an allogeneic tumor cell vaccine, as maintenance therapy for non-small cell lung cancer (NSCLC) may benefit patients who initiate immunotherapy within 12 weeks of completion of chemotherapy and those who have received prior radiation, a study published in the November issue of the European Journal of Cancer has shown.1

Belagenpumatucel-L is a therapeutic vaccine made up of 4 transforming growth factor (TGF)-β2-antisense gene-modified, irradiated, allogeneic NSCLC cell lines.

Previous studies have demonstrated that the vaccine may be useful for maintenance therapy after patients have received initial treatment.

For the phase 3 study, researchers enrolled 532 patients with stage 3 or 4 NSCLC who did not experience disease progression following platinum-based chemotherapy.

Participants were randomly assigned 1:1 to receive maintenance belagenpumatucel-L or placebo 1 to 4 months from the end of induction chemotherapy.

Results showed that median overall survival was 20.3 months with belagenpumatucel-L compared with 17.8 months with placebo (HR=.94; P=.594) and progression-free survival was 4.3 months and 4.0 months, respectively (HR=.99; P=.947).

RELATED: Nivolumab Benefits, Risks in NSCLC Detailed in Report

Despite no statistically significant difference in overall survival or progression-free survival between the 2 treatment arms, researchers found that the time elapsed between the end of induction chemotherapy and randomization had a significant impact on survival (P=.002) and that prior radiation improved survival as well (HR=.61; P=.032).

The authors concluded that further studies of the vaccine in NSCLC are warranted.

Reference

  1. Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumor cell vaccine, as maintenance therapy for non-small cell lung cancer. E J Cancer. 2015;51(16):2321-2329.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs